These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 2925259)

  • 1. Influence of different dialyzer membranes on plasma fibronectin levels in hemodialyzed patients.
    Pertosa G; Pastore A; Schena FP
    Int J Artif Organs; 1989 Jan; 12(1):36-40. PubMed ID: 2925259
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma fibronectin levels in patients with chronic uremia.
    Schena FP; Pertosa G; Germinario C
    Nephron; 1986; 44(4):320-3. PubMed ID: 3540692
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of aluminum removal between hemodialysis with polycarbonate low flux membrane and hemofiltration with polysulfone high flux membrane in end-stage renal failure patients.
    Klemm A; Sperschneider H; Winnefeld K; Günther K; Stein G
    Clin Nephrol; 1997 Feb; 47(2):133-4. PubMed ID: 9049466
    [No Abstract]   [Full Text] [Related]  

  • 4. Dialysis membranes for blood purification.
    Sakai K
    Front Med Biol Eng; 2000; 10(2):117-29. PubMed ID: 10898241
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The AN69 hemofiltration membrane has a decreasing effect on the intracellular diadenosine pentaphosphate concentration of platelets.
    Jankowski J; Schlüter H; Henning L; van der Giet M; Jankowski V; Zidek W; Tepel M
    Kidney Blood Press Res; 2003; 26(1):50-4. PubMed ID: 12697977
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasma fibronectin concentrations in hemodialyzed patients. Influence of different dialyzers.
    Schena FP; Pertosa G; Pastore A; Manno C; Pastore G
    Life Support Syst; 1985; 3(1):83-5. PubMed ID: 3990357
    [No Abstract]   [Full Text] [Related]  

  • 7. [Changes in the beta 2-microglobulin level during hemodialysis].
    Nikitinskaia LP; Stetsiuk EA; Iarmolinskiĭ IS; Barinov AV; Kon'kova TA
    Urol Nefrol (Mosk); 1990; (5):29-31. PubMed ID: 2264202
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effects of hemodialysis with different membranes on middle molecules and uremic neuropathy.
    Djukanović LJ; Mimić-Oka JI; Potić JB
    Int J Artif Organs; 1989 Jan; 12(1):11-9. PubMed ID: 2538398
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The treatment of hyperhomocysteinemia in patients on dialysis: folic acid or the high-flow polysulphonic membrane?].
    Lovcić V; Kes P; Zeljko R; Kusec V
    Acta Med Croatica; 2006 Jun; 60(3):201-8. PubMed ID: 16933832
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Membrane designs and composition for hemodialysis, hemofiltration and hemodialfiltration: past, present and future.
    Davenport A
    Minerva Urol Nefrol; 2010 Mar; 62(1):29-40. PubMed ID: 20424568
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Ways of intensification of hemodialysis therapy].
    Filiptsev PIa; Kirkhman VV; Timokhov VS
    Ter Arkh; 1988; 60(6):44-7. PubMed ID: 3206368
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aspects of biocompatibility of two different dialysis membranes: cuprophane and polysulfone.
    Amato M; Salvadori M; Bergesio F; Messeri A; Filimberti E; Morfini M
    Int J Artif Organs; 1988 May; 11(3):175-80. PubMed ID: 3261279
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Membranes for blood purification: state of the art and new developments.
    Strathmann H; Göhl H
    Contrib Nephrol; 1990; 78():119-40; discussion 140-1. PubMed ID: 2225829
    [No Abstract]   [Full Text] [Related]  

  • 14. Increased binding of beta-2-microglobulin to blood cells in dialysis patients treated with high-flux dialyzers compared with low-flux membranes contributed to reduced beta-2-microglobulin concentrations. Results of a cross-over study.
    Traut M; Haufe CC; Eismann U; Deppisch RM; Stein G; Wolf G
    Blood Purif; 2007; 25(5-6):432-40. PubMed ID: 17957097
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Atrial natriuretic peptide plasma levels during hemodialysis and hemofiltration in patients with end-stage renal disease.
    Groll J; Hagemann J; Röhrich B; Schaefer K
    Int J Artif Organs; 1989 May; 12(5):284-8. PubMed ID: 2525530
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro and in vivo evaluation of enoxaparin removal by continuous renal replacement therapies with acrylonitrile and polysulfone membranes.
    Isla A; Gascón AR; Maynar J; Arzuaga A; Corral E; Martín A; Solinís MA; Muñoz JL
    Clin Ther; 2005 Sep; 27(9):1444-51. PubMed ID: 16291417
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hyperleptinemia in uremic patients undergoing conservative management, peritoneal dialysis, and hemodialysis: A comparative analysis.
    Fontán MP; Rodríguez-Carmona A; Cordido F; García-Buela J
    Am J Kidney Dis; 1999 Nov; 34(5):824-31. PubMed ID: 10561137
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Beneficial effect of AN69 membranes on anemia in hemodialyzed patients].
    García Cortés MJ; Sánchez Perales MC; Liébana A; Gil JM; Borrego FJ; Borrego J; Pérez del Barrio P; Serrano P; Pérez Bañasco V
    Nefrologia; 2001; 21(4):370-5. PubMed ID: 11816513
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of blood coagulation-fibrinolysis system in patients receiving chronic hemodialysis.
    Ishii Y; Yano S; Kanai H; Maezawa A; Tsuchida A; Wakamatsu R; Naruse T
    Nephron; 1996; 73(3):407-12. PubMed ID: 8832598
    [TBL] [Abstract][Full Text] [Related]  

  • 20. N-terminal fragments of the proatrial natriuretic peptide in patients before and after hemodialysis treatment.
    Franz M; Woloszczuk W; Hörl WH
    Kidney Int; 2000 Jul; 58(1):374-83. PubMed ID: 10886584
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.